CRP and tuberculosis: Differences between these latter two subgroups were not discernible by clinical measures of their treatment response, such as CRP and x ray, at these early time points, supporting the utility of transcriptional biomarkers as more sensitive measures of the treatment response than existing clinical markers, to inform clinical management of TB patients and to support drug development platforms and future drug treatment trials.